4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $6.3B | $136M | 0.0% | 0.0% | — | $1.1B | $710M |
| 2024 | $6.0B | $210M | 0.0% | 0.0% | — | $1.1B | $557M |
| 2023 | $5.4B | $54M | 0.0% | 0.0% | — | $1.2B | $438M |
| 2022 | $5.1B | $189M | 0.0% | 0.0% | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1.6B | $40M | 0.0% | 0.0% | — | $1.1B | $610M |
| Dec '25 | $1.6B | $45M | 0.0% | 0.0% | — | $1.1B | $710M |
| Sep '25 | $1.6B | -$23M | 0.0% | 0.0% | — | $1.1B | $609M |
| Jun '25 | $1.6B | $73M | 0.0% | 0.0% | — | $1.1B | $541M |
| Mar '25 | $1.5B | $41M | 0.0% | 0.0% | — | $1.1B | $495M |
| Dec '24 | $1.6B | $114M | 0.0% | 0.0% | — | $1.1B | $557M |
| Sep '24 | $1.4B | $26M | 0.0% | 0.0% | — | $1.1B | $563M |
| Jun '24 | $1.5B | $43M | 0.0% | 0.0% | — | $1.1B | $335M |
| Mar '24 | $1.4B | $27M | 0.0% | 0.0% | — | — | — |
| Dec '23 | $1.3B | -$4M | 0.0% | 0.0% | — | $1.2B | $438M |
| Sep '23 | $1.4B | $21M | 0.0% | 0.0% | — | — | — |
| Jun '23 | $1.4B | $33M | 0.0% | 0.0% | — | — | — |
| Mar '23 | — | $4M | — | — | — | — | — |
How the market has priced ARDT against its own fundamentals since 2024-07 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Ardent Health, Inc.'s revenue has grown 7.2% per year, and net income declined 10.4% per year. These are computed facts, not advice.
As of FY2025, Ardent Health, Inc. reported $1.1B of total debt against $710M of cash.
In FY2025, gross margin was —, operating margin —, and net margin 2.1%.
As of Jun '26, Ardent Health, Inc. traded at a price-to-earnings ratio of about 9.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.